OBIO

Orchestra BioMed is not an operating business you can value on its numbers; it's a clinical-stage device developer whose flagship candidates — AVIM Therapy for hypertension (partnered with Medtronic, BACKBEAT pivotal enrollment targeted mid-2026) and Virtue SAB (740-patient IDE trial vs. Boston Scientific's AGENT, enrollment targeted mid-2027) — have not yet been approved or commercialized. The headline FY2025 revenue of $33.5M (+1169% YoY) is misleading: the company's own history shows recurring product revenue running $2.6–3.5M (FreeHold subsidiary), so the jump is a lumpy, non-recurring partnership/milestone recognition, not durable sales. Applying a 7.3x P/S to that number is meaningless.

The fundamentals are those of a cash-burning pre-revenue developer. FY2025 net loss was -$52.7M and operating cash flow was -$49.0M against just $34.7M of cash at year-end — under a year of runway on burn alone. Management states plainly it has incurred net losses every year since inception, expects to 'continue to incur significant losses for the foreseeable future,' and carries a -$362.6M accumulated deficit. R&D of $58.2M exceeds revenue, and shares outstanding rose 52.7% YoY — heavy, ongoing dilution is the funding model (cumulative $356.5M raised to date), which structurally caps per-share upside.